Logo

Horizon Therapeutics' Tepezza (teprotumumab-trbw) Receives the US FDA's Approval as the First Therapy for Thyroid Eye Disease

Share this

Horizon Therapeutics' Tepezza (teprotumumab-trbw) Receives the US FDA's Approval as the First Therapy for Thyroid Eye Disease

Shots:

  • The US FDA’s approval of Tepezza is based on P-II study and P-III OPTIC study assessing Tepezza vs PBO in patients with thyroid eye disease. Tepezza was initially developed by River Vision and Roche- later Horizon acquired River Vision and will pay ~$105M as milestones in H1’2020   
  • The P-III OPTIC study results: @24wks- improvement in proptosis (≥ 2 mm) (82.9% vs 9.5%) without deterioration in the fellow eye; change in at least one grade in diplopia (67.9% vs 28.6%). Pooled analysis demonstrated complete resolution of diplopia (53% vs 25%)
  • Tepezza (q3w- for 8 infusions) is mAb targeting IGF-1R and has received the US FDA’s PR- ODD- BT designation with its anticipated PDUFA date as 08 Mar- 2020. The therapy is expected to be available in the US in the coming wks.

Click here ­to­ read full press release/ article | Ref: Horizon Therapeutics | Image: Horizon Therapeutics


Tuba

Tuba was Senior Editor at PharmaShots. She was curious, creative, and passionate about recent updates and innovations in the life sciences industry. She covered Biopharma, MedTech, and Digital health segments. Tuba also had an experience in digital and social media marketing and ran the campaigns independently. She can be contacted at connect@pharmashots.com.

Share this article on WhatsApp, LinkedIn and Twitter

Related News/Articles

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions